Over the past three decades, generic medicines have significantly increased patient access to quality treatment, while lowering healthcare costs in the United States. Learn how a new class of prescription drugs knows as biosimilars, offers the same hope of increased access and reduced costs.
The 69th World Health Assembly, took place in Geneva on May 23 – 28, 2016, and USP was honored to co-host a high level discussion on global public health and the SDGs (Sustainable Development Goals). This article captures parts of the conversation that took place not only in Geneva but via social media as well.
In LMICs, the availability of medicines manufactured locally that do not meet quality standards is a leading cause of treatment failure and adverse events in patients and is undermining public health interventions. But where do things go wrong during pharmaceutical manufacturing in LMICs that give rise to this problem? Learn more.